Webinars and Commercial Conversations — Register Now
Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Illumina
| Company | Illumina |
|---|---|
| Name of system | MiSeq Dx |
| City, State | San Diego, CA |
| Phone | 858-202-4500 |
| Website | |
| System application/FDA cleared or approved | in vitro diagnostic and research use/yes |
| Country where designed/Manufactured | U.S./U.S. |
| First year sold in U.S./First year installed in U.S. | 2013/2013 |
| System sold internationally | yes (worldwide) |
| Dimensions of sequencer (H × W × D)/Footprint of sequencer | 20.6 × 27 × 22.2 in./4.2 sq. ft. |
| Accessory equipment supplied with sequencer at no cost | — |
| Type of computer supplied with sequencer | computer for analysis and operations combined |
| Analysis options provided with sequencer | onboard, cloud based |
| Where library preparation is performed | wet bench |
| Bioinformatics tools provided with sequencer | Local Run Manager, MiSeq Reporter, BaseSpace Sequence Hub |
| Sequencer supplied with UPS (uninterruptible power supply) | yes (extra charge) |
| Electrical connection required for sequencer | 100–240 VAC at 50/60 Hz, 10 A, 400 W |
| List price of entire sequencer and necessary components | $125, 000 |
| Purchase options | purchase, lease, reagent rental |
| Warranties offered | first year included with purchase; extended warranty available |
| Training included/Total time for basic training per operator | yes/<1 day |
| Training location/Follow-up training available | at customer site/yes (extra charge) |
| Maximum No. of samples amplified in a single amplification event | 384 samples |
| Read length/Percent bases >Q30 | up to 2 × 300 bp/80% (for 2 × 150 bp) |
| Paired-end capability/Tag lengths/Spans | yes/up to 2 × 300 bp/up to 550 bp |
| Fragment/Tag lengths/Spans | yes/up to 2 × 300 bp/up to 550 bp |
| Mate pair/Tag lengths/Spans | yes/up to 2 × 150 bp/2–12 kb |
| Single end/Tag lengths/Spans | yes/up to 1 × 300 bp/up to 300 bp |
| RNA sequencing/Tag lengths/Spans | yes/up to 2 × 300 bp/up to 550 bp |
| ChIP sequencing/Tag lengths/Spans | yes/up to 2 × 300 bp/up to 550 bp |
| Bisulfite sequencing/Tag lengths/Spans | yes/up to 2 × 300 bp/up to 550 bp |
| Maximum No. of reads or fragments sequenced per single-end run | >15 million |
| Maximum No. of reads or fragments sequenced per paired-end run | >30 million |
| Total No. of nucleotides (bases) sequenced per run | up to 7.5 Gb |
| Wet lab bench time for sequencing preparation | 10 minutes |
| Sequencing run time | <28 hours |
| Total time for generating standard gDNA library | <3.5 hours (with Illumina DNA Prep) |
| • Paired end | <3.5 hours (with Illumina DNA Prep) |
| • Fragment | <7 hours (with AmpliSeq for Illumina); <6.5 hours with Illumina DNA Prep with Enrichment) |
| • Mate pair | — |
| • Single end | <1 day (with TruSeq Small RNA) |
| • RNA sequencing | <9 hours |
| • Bisulfite sequencing | — |
| • Hands-on time for paired end | <1.5 hours (with Illumina DNA Prep) |
| • Hands-on time for fragment | <1.5 hours (with AmpliSeq for Illumina); <2 hours (with Illumina DNA Prep with Enrichment) |
| • Hands-on time for mate pair | — |
| • Hands-on time for single end | <4 hours (with TruSeq Small RNA) |
| • Hands-on time for RNA sequencing | <3 hours |
| • Hands-on time for ChIP sequencing | — |
| • Hands-on time for bisulfite sequencing | — |
| Library preparation integrated in system as standard offering | no |
| Cost of sequencing reagents per run | $2, 440 |
| Reagent tracking method | RFID |
| • Type of reagent information tracked | serial No., expiration date, lot and part Nos., No. of cycles |
| Shipping conditions for amplification/sequencing reagents | box 1: dry ice; box 2: gel pack/box 1: dry ice; box 2: gel pack |
| Storage conditions for amplification/sequencing reagents | box 1: -15°– -25°C; box 2: 2°– 8°C/box 1: -15°– -25°C; box 2: 2°– 8°C |
| Shelf life of amplification/sequencing reagents | guaranteed 6 months/guaranteed 6 months |
| System requires a control sample on sequencing run | optional |
| • Company offers a sequencing control | yes (additional charge) |
| Sequencing system control software and devices to start run/for data analysis | MiSeq Control Manager/Local Run Manager, MiSeq Reporter, BaseSpace Sequence Hub |
| Complete walkaway automation for amplification, sequencing, and variant calling | yes |
| Remote system monitoring | yes |
| Total time required for setup of amplification, sequencing, and variant calling steps | 10 minutes |
| Maximum No. of libraries sequenced in a single run | 384 samples (>384 samples with custom barcodes) |
| System includes secondary data-analysis software developed by company | yes (MiSeq Reporter, Local Run Manager, BaseSpace Sequence Hub) |
| System includes post-sequencing data-analysis software | yes (MiSeq Reporter, Local Run Manager, BaseSpace Sequence Hub) |
| Mutations detectable via data-analysis software | substitutions, indels, copy number changes |
| System can generate a variant report | yes |
| Types of maintenance plans available/mean time between failures | parts only, bronze, silver, gold, Dx, dedicated on-site/— |
| No. of field application scientists and engineers based in U.S. | >500 |
| • Weekly maintenance required | none (manual wash if instrument idle for 7 days) |
| • Monthly maintenance required | maintenance wash |
| • Pre-run maintenance required | none (post-run wash after every run) |
| Distinguishing features of NGS system (supplied by company) | FDA-regulated NGS platform allows clinical diagnostics in Dx mode and clinical research applications in research mode; FDA-regulated content includes MiSeqDx cystic fibrosis 139-variant assay, MiSeqDx cystic fibrosis clinical sequencing assay; leverages proven MiSeq technology |